18.02
3.21%
0.56
After Hours:
17.99
-0.03
-0.17%
Overview
News
Price History
Option Chain
Financials
Why TEVA Down?
Discussions
Forecast
Stock Split
Dividend History
Teva Pharmaceutical Industries Ltd Adr stock is traded at $18.02, with a volume of 6.07M.
It is up +3.21% in the last 24 hours and down -4.50% over the past month.
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$17.46
Open:
$17.61
24h Volume:
6.07M
Relative Volume:
0.74
Market Cap:
$20.42B
Revenue:
$16.29B
Net Income/Loss:
$-476.00M
P/E Ratio:
-9.01
EPS:
-2
Net Cash Flow:
$679.00M
1W Performance:
+1.69%
1M Performance:
-4.50%
6M Performance:
+27.71%
1Y Performance:
+76.67%
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Name
Teva Pharmaceutical Industries Ltd Adr
Sector
Phone
972 (3) 914-8213
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Nov-27-23 | Upgrade | UBS | Neutral → Buy |
Jul-06-23 | Upgrade | UBS | Sell → Neutral |
May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-04-22 | Downgrade | UBS | Neutral → Sell |
Oct-21-22 | Resumed | Jefferies | Buy |
Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
Jun-14-22 | Resumed | UBS | Neutral |
May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
Jan-27-22 | Downgrade | Argus | Buy → Hold |
Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-04-21 | Downgrade | UBS | Buy → Neutral |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Nov-25-20 | Initiated | Oppenheimer | Perform |
Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-27-20 | Resumed | Goldman | Neutral |
Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
Apr-24-20 | Resumed | Citigroup | Neutral |
Apr-06-20 | Upgrade | UBS | Neutral → Buy |
Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-10-19 | Resumed | Credit Suisse | Neutral |
Jul-05-19 | Upgrade | Argus | Hold → Buy |
Jun-11-19 | Initiated | Barclays | Underweight |
Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
May-28-19 | Downgrade | UBS | Buy → Neutral |
Mar-20-19 | Initiated | SunTrust | Hold |
Mar-07-19 | Resumed | UBS | Buy |
View All
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA): Worth A Small Bite At $17.54 - Stocks Register
How will Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) earnings compare to estimates this quarter? - US Post News
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Shares Jump Approximately 70.34% Over the Year - Knox Daily
Before You Invest, Make Sure You Check This New Oriental Education & Technology Group Inc. ADR (NYSE: EDU) Analysis – Stocks Register - Stocks Register
TEVA’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle
Does Walmart Inc (NYSE: WMT) Still Need To Convince Analysts? - Stocks Register
When Would Be The Best Time To Buy UiPath Inc (NYSE: PATH) Stock? - Stocks Register
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Stock trading around $17.72 per share: What’s Next? - The DBT News
Checking in on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insiders movement - Knox Daily
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY (risperidone) Extended-Release Injectable Suspension from Perseris (RBP-7000) - wallstreet:online
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia - GlobeNewswire Inc.
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) - GlobeNewswire Inc.
DLTR Shares Experience Surge in Value - Knox Daily
A company insider recently sold 708 shares of NAPCO Security Technologies Inc [NSSC]. Should You Sale? - Knox Daily
Views of Wall Street’s Leading Experts on Teva- Pharmaceutical Industries Ltd. ADR - SETE News
Keeping an Eye on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) After Insider Trading Activity - Knox Daily
Weekly Upgrades and Downgrades - InvestorPlace
Weekly Upgrades and Downgrades - MSN
TEVA Shares Experience Surge in Value - Knox Daily
Does Teva- Pharmaceutical Industries Ltd. ADR (TEVA) offer a good opportunity for investors? - SETE News
Global Buccal Drug Delivery Systems Market Research 2024-2030 Featuring Johnson & Johnson, Pfizer, Sanofi, Novartis, Bayer, Teva Pharmaceuticals, AbbVie, Cipla, and Haleon - GlobeNewswire Inc.
How analysts predict Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will perform this quarter? - US Post News
Argus analysts upgrades a Buy rating for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - Knox Daily
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies - Benzinga
Teva- Pharmaceutical Industries Ltd. ADR Inc. (TEVA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability - Benzinga
What will the future hold for Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) stock? - US Post News
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production - Benzinga
Insider Selling: Daniell Richard, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Exec. VP, European Commercial divested 98,943 shares – Knox Daily - Knox Daily
insider CHURAY DANIEL J sale 16,975 shares of MRC Global Inc [MRC] - Knox Daily
Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report - GlobeNewswire Inc.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Daniell Richard sells 98,943 Shares for $1.71 million - Knox Daily
Tardive Dyskinesia (TD) Market Research 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access - GlobeNewswire Inc.
Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030 - GlobeNewswire Inc.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) expanding its growth trajectory ahead - SETE News
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Records 200-Day SMA of $13.98 - Knox Daily
Respiratory Drugs - GlobeNewswire Inc.
For Teva- Pharmaceutical Industries Ltd. ADR [TEVA], Analyst sees a rise to $20. What next? - The DBT News
Understanding TEVA stock ratios for better investment decisions - US Post News
TEVA stock rated a Buy by Argus - Knox Daily
Teva: Simlandi to See Share Gains in a Growing Humira Biosimilar Market Thanks to Formulary Update - Morningstar
Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider - GlobeNewswire Inc.
Teva- Pharmaceutical Industries Ltd. ADR’s Banking’s 100-Day Moving Average at 16.15: Will the Stock Break Through? - The InvestChronicle
Premature Ejaculation Treatment Business Research Report 2024 Featuring Absorption Pharma, Allergan, AstraZeneca, Bayer, Eli Lilly and Co, GSK, Innovus, Merck, Pfizer, and Teva - GlobeNewswire Inc.
Multiple Sclerosis (MS) Diagnosis and Treatment Market Size to Reach USD 30.28 Bn by 2032 - GlobeNewswire Inc.
Global Acetaminophen-Opioid Combination Market Growth Accelerating Due to an Impressive USD 4,522.6 Million by 2034 Increased Usage in Cancer-Related Pain: Future Market Insights - GlobeNewswire Inc.
Is SoundHound AI Stock a Buy Now? - The Motley Fool
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Shares Jump Approximately 88.62% Over the Year - Knox Daily
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - GlobeNewswire Inc.
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):